Exabis Library
Welcome to the e-CCO Library!
P610: Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P610: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P610: Risk of active Hepatitis B and C infections in the Phases 2 and 3 clinical trial programmes for ustekinumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P610: Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P611: A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P611: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN'S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P611: Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P611: Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P611: Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P611: Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P612: Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activity
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P612: Immunosuppressive co-treatment with infliximab and adalimumab is not superior to anti-TNF monotherapy to prevent treatment failure and treatment discontinuation in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P612: Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P612: Long-term outcomes of treatment intervention according to the severity of small bowel capsule endoscopy findings in patients with Crohn’s disease: A Japanese single-centre cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P612: Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P612: Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P613: Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM